Sodium nitrite SR is under clinical development by JanOne and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Sodium nitrite SR’s likelihood of approval (LoA) and phase transition for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) took place on 11 Nov 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sodium nitrite SR Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Sodium nitrite SR overview

Sodium nitrite is under development for the treatment of peripheral artery disease (PAD), ischemia and endothelial cell dysfunction in COVID-19 patients. The drug candidate is a sustained release formulation and is administered orally. Sodium nitrite therapy increases ischemic tissue nitrite and NO (nitric oxide) metabolites compared to nonischemic limbs. The drug candidate was also under development for the treatment of systemic sclerosis (Scleroderma), diabetic neuropathic pain and diabetic peripheral neuropathy diabetic foot ulcers, arterial aging and aging.

JanOne overview

JanOne, formerly Appliance Recycling Centers of America Inc, is a pharmaceutical company. The company discovers and develops treatment for diseases causing severe pain and in the verge of prescribing opioid medications. JanOne pipeline product includes which is engaged in assisting the use of sodium nitrite as a non-addictive treatment for diabetic neuropathy and to treat peripheral artery disease (PAD). The company, through its subsidiary, develops and sells cellular transceiver modules and also offers recycling of appliances and replacement services for household and electric utilities. The company operates in the US and Canada. JanOne is headquartered in Las Vegas, Nevada, the US.

Quick View Sodium nitrite SR LOA Data

Report Segments
  • Innovator
Drug Name
  • Sodium nitrite SR
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.